Sen-Jam Pharmaceutical offering is now closed and is no longer accepting investments.

INVEST IN SEN-JAM PHARMACEUTICAL TODAY!

Revolutionizing Anti-inflammatories for Life

Sen-Jam Pharmaceutical is developing a line of anti-inflammatory drugs designed to provide a much-needed update to a multi-billion dollar market that has seen little innovation in the past 30 years, or since aspirin was invented 125 years ago. We are developing 12 different drugs targeting 7 therapeutic areas intended to reduce pain and inflammation by harnessing your body’s immune system, at the very beginning of the inflammatory cascade. We seek to prevent acute inflammation, slow the progression of inflammatory chronic illnesses, and improve health span. According to our research, there are no pharmaceutical products available to the consumer, either Over-the-Counter (OTC) or prescription (Rx), that acts so early, and safely, at the very beginning of inflammation. Our initial drugs are pre-market, patented, and will seek FDA-approval. Sen-Jam is currently enrolling patients in our covid oral therapeutic Phase 2 Clinical Trial in collaboration with Duke University. Sen-Jam is also ready to begin our Phase 2 clinical trial for prevention of alcohol’s toxic effects. Because we repurpose small molecules with over 30 years of safety data, we are able to bring these new pharmaceuticals to the consumer rapidly, using an accelerated FDA pathway for approval.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Sen-Jam Pharmaceutical

$309,476.07 Raised

REASONS TO INVEST

Reasons Icon

We are harnessing the technology of mast cell modulators (the very beginning of the inflammatory/immune cascade) to boldly introduce to the consumer a safer more effective approach to reducing inflammation, before it leads to chronic illness. Sen-Jam is a human-first revolution in the Trillion Dollar anti-inflammatory market that seeks to improve health span.

Reasons Icon

Our drugs are designed to have widespread applications, from covid-19 treatment to opioid withdrawal, alcohol hangovers, arthritis, and vaccine administration (all interconnected by inflammation) amounting to a total addressable market estimated at $217 billion. Because our drugs are safe, some will be OTC; some will be introduced as Rx and we will seek to have them join the OTC arena, to increase accessibility and decrease cost to the consumer; some drugs will be injectable for urgent hospital use.

Reasons Icon

We are led by a team of entrepreneurs, innovators, scientists and futurists with decades of experience in operations and pharmaceuticals, as well as a combined $730 million in successful exits.

Revolutionizing Inflammatory and Pain Management So Humanity Can Thrive


At Sen-Jam Pharmaceuticals, we believe we are reconstructing and disrupting the entire anti-inflammatory market with a suite of drugs ranging from OTC to Rx that embrace mast cell modulators as the future of anti-inflammatory relief. We reformulate safe, trusted drug compounds, some that are currently unavailable, orally, in the United States, to improve clinical outcomes for patients battling opioid use disorder, viral respiratory infections, acute and chronic inflammatory conditions, and even the infamous hangover.  



According to our research, we are the only company pursuing a more gentle mast cell modulator as a path to anti-inflammation, for everyday needs. 

The Problem & Our Solution


Empowering Consumers to Reclaim Their Pain and Inflammation Management


Rising rates of arthritis, the ongoing Covid-19 pandemic, the opioid crisis, and premature aging are all interconnected by rampant inflammation. As a result, American life expectancy has dropped by two years since 2020 (source). Meanwhile, major pharmaceutical companies have lost the trust of consumers when it comes to pain relief after the opioid crisis. Yet, a new oral anti-inflammatory pain reliever has not been introduced to the consumer in over 30 years.  Consumers who are determined to lower their individual inflammation, have resorted to clinically untested alternatives. 


We combined common, safe chemical compounds from two distinct categories of anti-inflammatories, to create a line of drugs designed to take a better approach to combat inflammation. In our research, we found these molecules reduce the rate at which immune system cells called mast cells release proteins that cause inflammation. This approach stops inflammation at the immediate root source, the very beginning of the inflammatory cascade, preventing the long-term tissue damage that causes many health problems.  We believe we have created the most potent, oral, anti-inflammatory drugs with the least side effects, with over 30 years of safety data. 



The Market & Our Traction


Game-Changing Treatments in Multiple Major Markets


We have designed twelve products targeting seven different therapeutic areas, ranging from over-the-counter to prescription strengths, often with multi-use, multi-organ applications. As a result, Sen-Jam Pharmaceuticals has the potential to reach patients in multiple major markets, including arthritis, respiratory infections, Covid therapeutics, opioid withdrawal, vaccine administration, and even alcohol hangovers. That makes our total addressable market an estimated $217 billion. 


(source, source, source, source, source, source, source



Since our launch, we have achieved the following milestones: 


Because we are repurposing existing small molecules, we plan to fast-track our regulatory pathway via 505(B)2 FDA approval. Meanwhile, our international patents provide a wide wingspan for global commercialization.


Why Invest


Developing the Next Generation of Anti-Inflammatory Drugs



We call ourselves the Good Karma Pharma People because our mission is to use innovation and transparency to improve societal well-being across the globe. Over the next few years, we plan to leverage our operational excellence and evidence-based science to advance our anti-inflammatory therapeutics to commercialization - all while expanding our asset base and global licensing. 


We will be using some of the funds from this raise towards:


*For a full description of the use of proceeds from this offering please see the Use of Proceeds section of the Offering Memorandum


With patented technology, diverse use cases across multiple billion-dollar markets, and strong strategic partnerships, we are ready to build the future of anti-inflammatory treatments, bringing everyone a much-needed solution. 







Bold (⌘B)
Code View
Code View

ABOUT

HEADQUARTERS

35 Fort Hill Drive
Lloyd Harbor, NY 11743
VALUATION

$69.98M
PREVIOUSLY CROWDFUNDED

$1M

Sen-Jam Pharmaceutical is developing a line of anti-inflammatory drugs designed to provide a much-needed update to a multi-billion dollar market that has seen little innovation in the past 30 years, or since aspirin was invented 125 years ago. We are developing 12 different drugs targeting 7 therapeutic areas intended to reduce pain and inflammation by harnessing your body’s immune system, at the very beginning of the inflammatory cascade. We seek to prevent acute inflammation, slow the progression of inflammatory chronic illnesses, and improve health span. According to our research, there are no pharmaceutical products available to the consumer, either Over-the-Counter (OTC) or prescription (Rx), that acts so early, and safely, at the very beginning of inflammation. Our initial drugs are pre-market, patented, and will seek FDA-approval. Sen-Jam is currently enrolling patients in our covid oral therapeutic Phase 2 Clinical Trial in collaboration with Duke University. Sen-Jam is also ready to begin our Phase 2 clinical trial for prevention of alcohol’s toxic effects. Because we repurpose small molecules with over 30 years of safety data, we are able to bring these new pharmaceuticals to the consumer rapidly, using an accelerated FDA pathway for approval.

TEAM

James Iversen
James Iversen
CEO, Co-Founder & Director

Executive with a consistent track record of designing + executing business strategies that deliver rapid growth in sales, profits, market share + customer satisfaction. Client remits include start-ups to late stage, often resulting in M&A transaction

Jacqueline M. Iversen
Jacqueline M. Iversen
Chief Clinical Officer, Co-Founder & Secretary

Jackie has extensive knowledge + capabilities in a multitude of clinical settings. Her expertise involves providing clinical pain education + having completed a research fellowship in pharmacokinetics + pain at Memorial Sloan Kettering Cancer Center.

Neal Zahn

Neal Zahn

Director of Global Licensing

Wildly successful and seasoned executive in the manufacturing, operations and pharmaceutical industries. Strong bench of skills in the business development space and has fine tuned his legendary resourcefulness in building long lasting, high impact strategic alliances. Charming and unflappable, bringing optimism and pragmatism to the global stage.

Christine Leonard

Christine Leonard

Head of Strategic Communications

Christine is a highly respected and award-winning marcom strategist with passion for brands that aim to improve lives. She has led marketing, consumer insight mining and communications development for world class healthcare companies big and small. She was involved with launching the global Blockbuster brand Dupixient and has a keen understanding of driving success in commerce with both healthcare professionals and consumers across many inflammatory brands.

Tom Dahl

Tom Dahl

Head of Product Development and Regulatory Affairs

Accomplished biotech/ pharmaceutical executive with deep expertise in early stage ventures, including technical analysis of products and technologies, business strategy and operations, development, clinical trial design and interpretation. Tenacious and well connected, helping to drive successful outcomes in both the clinical and regulatory arenas.

Alexander Wissner-Gross

Alexander Wissner-Gross

Advisor

Dr. Alexander D. Wissner-Gross is an award-winning scientist, inventor, entrepreneur, and angel investor. He serves as President and Chief Scientist of Gemedy and holds academic appointments at the Harvard Institute for Applied Computational Science, the Harvard Innovation Lab, and the MIT Media Lab. He has received 123 major distinctions, authored 18 publications, been granted 23 issued, pending, and provisional patents, and founded, managed, and advised 7 technology companies, 3 of which have been acquired. A popular TED speaker, his talks have been viewed almost 2 million times and translated into 27 languages. His work has also been featured in more than 180 press outlets worldwide including The New York Times, CNN, USA Today, the Wall Street Journal, and BusinessWeek.

Dr. Frank Farraye

Dr. Frank Farraye

Scientific Advisor

Dr. Farraye is a Senior Associate Consultant in the Section of Gastroenterology and Hepatology and Professor of Medicine at the Mayo Clinic in Jacksonville, Florida where he directs the Inflammatory Bowel Disease Center. Prior to relocating to Mayo in 2019, he was Clinical Director in the Section of Gastroenterology and the Inflammatory Bowel Disease Center at Boston Medical Center and Professor of Medicine at the Boston University School of Medicine. Dr. Farraye earned his medical doctorate from the Albert Einstein College of Medicine in New York and his master's degree in Epidemiology from the Harvard School of Public Health.

TERMS

Sen-Jam Pharmaceutical
Overview
PRICE PER SHARE
$7.35
DEADLINE
Jan 12, 2023
VALUATION
$69.98M
AMOUNT RAISED
$309,476.07
Breakdown
MIN INVESTMENT
$294.00
MAX INVESTMENT
$1,007,192.55
MIN NUMBER OF SHARES OFFERED
1,360
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
543,237

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

Sen-Jam Pharmaceutical Inc.

Corporate Address

:

35 Fort Hill Drive, Lloyd Harbor, NY 11743

Offering Minimum

:

$9,996.00

Offering Maximum

:

$3,992,791.95

Minimum Investment Amount

(per investor)

:

$294.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

1,360

Maximum Number of Shares Offered

:

543,237

Price per Share

:

$7.35

Pre-Money Valuation

:

$69,979,019.25











*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of his or her authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Transfer Restrictions Applicable to Securities Sold in this Offering

Section 7.1(a) of bylaws of the Company (the “ByLaws”) details the right of first refusal (“ROFR”) restriction applicable to the Common Stock sold in this offering. In short, if a selling stockholder receives a bona fide offer from a third party to purchase all or any portion of such stockholder’s shares of stock and the selling stockholder wishes to accept such offer, the selling stockholder must first provide Sen-Jam with prompt written notice (“Sale Notice”). Upon receipt of such notice, Sen-Jam may elect to purchase the shares or waive its purchase right, all subject to the procedures and applicable notice periods, as detailed in Section 7.1(a) of the Bylaws.

Section 7.2 (a) - (g) of the Bylaws provides for additional transfer restrictions, including but not limited to: (1) ineligible transferee; (2) competitor transferees; (3) the transfer would result in a breach of laws or regulations if consummated; (4) the transfer would result in the corporation or its stockholders incurring liability; (5) the transfer would result in a registration or filing requirement on behalf of the Company; (6) the transfer would result in a loss of federal or state exemption; and (7) the transfer or the transferee would be harmful or injurious to the business or reputation of the Company. Each of the foregoing will be enforced by the Board of Directors of the Company (the “Board”) in its sole discretion.

Section 7.3 of the Bylaws details exemptions to the transfer restrictions of Sections 7.1 and 7.2 of the Bylaws.

Drag-Along Right Applicable to Securities Sold in this Offering

Section 7.5 of the Bylaws provides for a Drag-Along Right. In short, if the Board votes to approve any sale or change in control of the Company, then each stockholder must consent to, and agree to raise no objections against, such transaction and take all necessary or desirable actions to facilitate the consummation of such transaction as requested by the Company. Additional obligations and information are outlined in Section 7.5 (a)-(c) of the Bylaws.

SJP Owner Network Bonus (Loyalty Bonus)

The Company would like to offer you an additional 10% bonus shares of your total investment.

Time-Based:

Friends and Family

Invest within the first week and receive 15% bonus shares

Super Early Bird Bonus

Invest in the second week and receive 10% bonus shares

Early Bird Bonus

Invest in the third week and receive 5% bonus shares

Amount-Based:

$1,000+│ Tier 1

The Company would like to offer you an additional 3% bonus shares of your total investment.

$5,000+ │ Tier 2

The Company would like to offer you an additional 7% bonus shares of your total investment.

$10,000+ │ Tier 3

The Company would like to offer you an additional 10% bonus shares of your total investment.

$20,000+ │ Tier 4

The Company would like to offer you an additional 12% bonus shares of your total investment.

$25,000+ │ Tier 5

The Company would like to offer you an additional 15% bonus shares of your total investment.

$50,000+ │ Tier 6

The Company would like to offer you an additional 20% bonus shares of your total investment.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners’ Bonus

The Company will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. Owner’s bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example (assuming no other eligible bonuses), if you buy 100 shares of Common Stock at $7.35 / share, you will receive 110 shares Common Stock, meaning you’ll own 110 shares for $735. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the Company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the SJP Owner Network Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative.

ALL UPDATES

01.11.23

This is your Chance: Last few hours until our Campaign Closes

Rounding the corner into Day Three of JPMorgan Healthcare Conference and the clock is ticking loudly.

TODAY IS YOUR LAST DAY TO INVEST here on StartEngine.  Please make your move.

Join us and the many others who are growing the momentum and making this opportunity to revolutionize anti-inflammatories with our platform a global reality.  All the pieces are in place now and the energy is percolating. We have had a ton of interest here at the conference and even had our swag being shared and making a splash.

We've had tremendous meetings and Jackie did an amazing job with her presentation.  You can see a quick snapshot here.

But today is the day.  You have until 11:59pm EST to make your move.  Thank you for your continued support - it takes a village to change the world and that's our mission.  We are grateful to each and every one of you.

Let's do this!

Jim

01.10.23

There's no place like...Home Stretch!

Dear Investors, Colleagues, and Friends,

Ran into a new friend at one of the evening events in town.  Dr. Oz was chatting it up with our team and expressed his enthusiasm for what we are doing around anti-inflammatories at Sen-Jam Pharmaceutical.  Jackie was beaming.

And yes, this was just Day One at the JP Morgan Healthcare Conference and the number of companies, meetings and handshakes the SJP team has had already is fast approaching the 100 mark.   

But the best day of all for us, is today because this afternoon, at 4:45pm PST, Co-Founder and Chief Clinical Officer, Jackie Iversen RPh MS, will be illuminating to the attendees at BioTech Showcase the game-changing technology that is the Sen-Jam Platform of Next Generation Anti-Inflammatories.  Wish you could be here?  Well we have great news.  You can watch her talk virtually as she gives it without missing a beat. To register to watch her 15 minute BioTechTALK live, please click this link here

And yes, we need to remind you that there is only two days left to grab your piece of this remarkable company and take an ownership role, joining the over 430 investors that have contributed to the high vibe momentum.  Big investors are asking about us and this is extremely fortunate timing for you to jump in on our StartEngine campaign while the getting it good. Please join us and pay homage to that age old investment wisdom “buy low, sell high” – you won’t want to regret it later.

Let’s do this!

Jim

01.09.23

The Countdown, Success and the Role of De-Risking

Happy Monday Investors, Colleagues, and Friends,

The Sen-Jam team is in San Francisco sharing our great work with the investment community at the JP Morgan Healthcare Conference. We have spent the last 5 years masterfully de-risking our portfolio and pushing the limits to be the world's most resourceful drug developer. The world has its eyes on us now.

Successful investing in innovation requires the discipline of risk management by both the company and its investors. We have spent those five years de-risking the development and delivery of this new drug platform to the market. We have communicated why a proper portfolio position in our company would be an easy choice for a properly risk-managed investment portfolio.

This opportunity for you to participate ends in just 3 days. Please consider making an investment in Sen-Jam Pharmaceutical. Also, if you recently had an exit (lucky you), you might be able to roll over your profits PRE-TAX into our current round under a 1045 Exchange if it's within a 60-day window. Then, when we have our exit, up to $10M of your profits will be tax-free.

It sounds like a great week is upon us. Let's do this!

Jim

01.06.23

What a Difference One Week Will Make! JOIN US NOW!

Next week will change the game for us. Are you ready?

First of all, we will be presenting at the 41st Annual JP Morgan Healthcare Conference in front of thousands of investors and institutional forces.  Our story of our revolutionary science and the impact our assets will have as true game-changers in the pharma industry will reverberate loud and clear.

If you are thinking about joining our efforts through StartEngine, the time to act is NOW.  As our campaign here will close to everyday men and women like yourselves on the 11th.  This is your last week (less than a week!) to become an owner in a true "good karma pharma" company through StartEngine.

If you or a peer would like to take advantage of this opportunity, we invite you to do so now without haste.

We have an incredible portfolio, built from a "golden goose" of a technology platform that we believe (and esteemed scientists around the world agree!) will become the next generation of anti-inflammatories.  Please join us and please share this link with your community.

Be inspired and nurture your soul by joining our mission to impact humanity!

Thank you!

Jim

12.27.22

Got Hangovers? Help is on the way!

Every year the holiday season sparks interest in can anything help a hangover?  At Sen-Jam Pharmaceutical we are very excited that 2023 will give us the opportunity to answer this question directly.  More on this in a minute.

 

Alcohol consumption can cause unpleasant physical and mental effects, commonly referred to as a “hangover”. Hangovers typically consist of headache, nausea, fatigue, and dehydration. For years, people have tried various methods to reduce the severity of hangover symptoms. Over the last decade we have seen an explosion in the availability of hangover treatments on the market. From pills containing vitamins and herbs to concoctions such as “hangover tea” or “recovery shots”, many of these treatments promise to reduce the severity of hangovers. However, most of them lack evidence-based science to support their claims and safety for public use. 

 

The global hangover treatment market is estimated to grow at a Compounded Annual Growth Rate (CAGR) of 14.6% from 2021-2028 and is ripe for a safe and efficacious solution. The need for more safety and efficacy testing on currently available treatments has never been greater. With the right solution, we can all enjoy a pleasant day even after a night out with friends. 

 

In order to create a safe and effective hangover treatment, it's important to understand the underlying biology of how alcohol affects our bodies. One of the key factors that contribute to hangover symptoms is inflammation. Alcohol consumption causes an increase in oxidative stress and inflammatory cytokines which can lead to dehydration, nausea, fatigue, headache, and other hangover symptoms. Additionally, inflammation can aggravate existing health conditions such as cardiovascular disease and diabetes. Thus, understanding the role of inflammation in hangovers is key to developing effective treatments that reduce their severity.

 

Armed with our leading scientific advisors, several international patents and a successful proof of concept, Sen-Jam Pharmaceutical is ready to begin it’s FDA approved phase 2 study to show efficacy in the reduction of symptoms associated with alcohol hangover.  At Sen-Jam we are focused on operational excellence and evidenced based research.  With the right research and development, we can develop safe, reliable, and efficacious treatment that is suitable for public use. This could revolutionize how people deal with hangovers and provide relief without compromising safety.

 

Investment dollars are necessary to fund the research in hangover treatments, so that we can confidently recommend them to our friends and families. Let's make sure we have safe options for all!

 

With only 2 weeks left for everyday people like yourself into invest, and change the course of hangover history, I want to encourage you to act now and invest.  Time is running out… Say good-bye to the dreaded hangover, and hello to full strength living. 

 

Be safe the holiday season and drink responsibly.

 

Jim

 

 

 

 

 

12.27.22

A Spectacular Year in Review!

It has been a momentous year for Sen-Jam Pharmaceutical! We have achieved noteworthy milestones in the direction of our mission to be the most resourceful pharmaceutical company in the world preventing inflammatory disease.

This past year, we have seen tremendous growth in our R&D activities and technical achievements. We welcomed new team members who have assisted us in making significant advances in the development of preventative treatments and cures. Our new patents, papers, and products will open the door to more efficient and personalized medical care. We also strengthened our partnerships with key industry stakeholders, allowing us to access the latest technologies and resources needed to advance our ant-inflammatory therapeutics.

Looking ahead to 2023, we are determined to build on this progress and make further strides toward advancing our products toward FDA approval. Our aim is to continue pushing innovation in medicine and redefining what’s possible for the future of healthcare.


Find linked here our “2023 Operating Plan – Advancing our Lead Assets to Prevent Disease” which marks the progress we have made to date and highlights our goals for next year of completing two – Phase II Clinical Trials, opening an IND to begin the 3rd Phase II Clinical Trial, and completing the Pre-IND work to advance two – Injectables to Phase I.

Our team is confident that with continued dedication and hard work, Sen-Jam Pharmaceutical will continue developing groundbreaking treatments for years to come. We are excited to share more details on our progress in the coming year and look forward to continuing to make a positive impact on global healthcare.

Thank you for your continued support,

Jim Iversen

CEO, Sen-Jam Pharmaceutical


12.21.22

Gifting this Holiday Season! Only 21 days left

Hello Investors, Colleagues, and Friends,

Just a few short days are left in this Holiday gifting season and we wonder if you, like us, appreciate the rich psychology of giving. Researchers have proven to us that there is legitimate brain chemistry supporting the positive feelings we experience when we engage in the act of giving. Whether by surprising loved ones with tokens of affection, donating to a worthy cause, or volunteering time, it feels good to give.

With that mindset as our backdrop, we want to propose something uncommon this year. What if, this season, on top of all you do and give for others in your life, you gave your future self a surprisingly unlikely gift of owning a part of a revolutionary entrepreneurial pharmaceutical company?

So it goes something like this - Today, this week (a.k.a. soon), you jump to our campaign page (Click HERE) and invest whatever amount you feel called to in Sen-Jam’s crowdfunding campaign. This is a novel opportunity to participate in a Series A funding round. Flash forward to future Christmases and imagine what might be possible for you then.

It may just please the Dickens out of ya.

Merry Christmas, Happy Hanukkah, Happy Kwanzaa, and all the rest to you and your families. May 2023 bring you great health, happiness, and prosperity.

Sincerely,

Your Friends at Sen-Jam Pharmaceutical

12.15.22

New Information on Inflammation: You're Going to Want to Check This Out!

Last week, Forbes published a great article on the latest and greatest in Inflammation Research and discovery, introducing the world to Mast Cells. We were thrilled as this little-known immune gatekeeper is at the forefront of our therapeutic platform's technology. I wholeheartedly encourage each of you to read it HERE.

Science can sometimes be hard to make clear sense around. And yet, we think first learning about Mast Cells might suggest it's hard to comprehend. But actually, it isn't. We are surprised how most folks expect things to be overly complicated when it comes to drug development. This is part of why Jackie Iversen RPh MS, (Sen-Jam's Co-Founder and Chief Clinical Officer) was invited to speak at this year's JP Morgan Healthcare Conference. 

This topic is gaining momentum and with good reason. Inflammation is a normal and everyday response impacting every man, woman, and child on this planet. One of Jackie's favorite lines around the office is, "Inflammation occurs frequently, intermittently, and knowingly." Mast cells are the key to the kingdom, and this Forbes article helps bring a laymen's understanding of the topic.

For more scientific detail, we invite you to watch a short, 3-minute video clip of our clinical research colleague and friend, Pantea Kiani. She is a well-known Google scholar who understands the importance of Ketotifen and its impact on our immune system, namely our Mast Cells which are critical, particularly when tackling COVID-19 infections. To learn more about Pantea, click here. You can see the video of her talking about our platform and the mechanism of action for mast cells HERE.

We are living in exciting times! Thanks for staying on this fascinating train to get important medications that will help billions of people in a powerful way to market using common sense and ingenuity with us. We pride ourselves on being the most resourceful drug development company in the world. We want everyone to know what we know and be as optimistic as we are about what's possible for humanity with the Next Generation of Anti-Inflammatories.

And remember, for a limited time, and as little as $294, you can impact (and profit from) positively affecting the course of humanity. Invest now HERE. Don't delay, there are 27 days left in this capital campaign. Our traction is palpable, and this is a unique opportunity for everyday investors to own a piece of healthcare history.

Thank you!

Jim

12.14.22

Impact Investing: Achieving Wealth by Doing Real Good

Ask yourself:

  • Has your life been affected by the outbreak of Covid over the last couple of years?
  • Are you worried about mysterious issues surrounding Long Haulers?  We are!
  • Has your family or friends suffered from the crippling effects of opioid addiction?
  • Do you or others you know miss out on being your best self after enjoying a libation or two?

Here is your chance to stop thinking or just talking about it and actually do something about it!  Sen-Jam Pharmaceutical has a platform of agents in or near FDA phase 2 clinical trials to address these issues.  Imagine having skin in the game for what hopes to become the world's very first FDA-approved Alcohol Hangover Prevention?  Or to be a part of a novel oral, safe and effective agent that holds promise to tackle the cytokine storm surrounding COVID so you not only treat the coronavirus infection, you may even (perhaps all the more importantly!) mitigate the neuroinflammation that leads to brain dog and other only now emerging mysterious long hauler affects?  

For a limited time and as little as $284 you can impact (and profit from) positively affecting the course of humanity.  Invest now, StartEngine.com/sen-jam.  Don't delay. Our traction is palpable and this is an extremely unique opportunity for everyday investors to literally own a piece of healthcare history.

We mean it when we are called to owning the affectionate title of the "Do No Harma Pharma" people.  And our Founder and Visionary Pharmacist, Jackie Iversen RPh MS has been among the few selected to speak at this upcoming JP Morgan Health Conference in San Francisco in early January.  The movers and shakers in healthcare investing are starting to pay very close attention to this Eureka moment Jackie had a few years ago of combining small molecules to bring to humanity what is arguably the world's most potent, safe, broad spectrum anti-inflammatory portfolio applicable to a wide variety of some of humanity's worst ailments.  Our platform truly reflects the most powerful advancement in the inflammatory world in three decades, if not in 125 years since Hoffman invented aspirin.  Check out also, The Opportunity Network because there is a special guest featured on their homepage...For good reason.

As always, we thank you for your interest and support and ask you to reach out to your peers to help this ship rise to the occasion and truly live our mission of wanting to improve societal wellbeing (which includes providing a healthy return for everyday men and women like yourselves).  

Now that's what we call a win-win in Impact Investing....

Jim

12.14.22

New Information on Inflammation: You'll Want to Know

Last week, Forbes published a great article on the latest and greatest in Inflammation Research and discovery, introducing the world to Mast Cells. We were thrilled as this little-known immune gatekeeper is at the forefront of our therapeutic platform's technology. I wholeheartedly encourage each of you to read it HERE.


Science can sometimes be hard to make clear sense around. And yet, we think first learning about Mast Cells might suggest it's hard to comprehend. But actually, it isn't. We are surprised how most folks expect things to be overly complicated when it comes to drug development. This is part of why Jackie Iversen, RPh MS, (Sen-Jam's Co-Founder and Chief Clinical Officer) was invited to speak at this year's JP Morgan Healthcare Conference. 


This topic is gaining momentum and with good reason. Inflammation is a normal and everyday response impacting every man, woman, and child on this planet. One of Jackie's favorite lines around the office is, "Inflammation occurs frequently, intermittently, and knowingly." Mast cells are the key to the kingdom, and this Forbes article helps bring a laymen's understanding of the topic.


For more scientific detail, we invite you to watch a short, 3-minute video clip of our clinical research colleague and friend, Pantea Kiani. She is a well-known Google scholar who understands the importance of Ketotifen and its impact on our immune system, namely our Mast Cells which are critical, particularly when tackling COVID-19 infections. To learn more about Pantea, click here. You can see the video of her talking about our platform and the mechanism of action for mast cells HERE.


We are living in exciting times! Thanks for staying on this fascinating train to get important medications that will help billions of people in a powerful way to market using common sense and ingenuity with us. We pride ourselves on being the most resourceful drug development company in the world. We want everyone to know what we know and be as optimistic as we are about what's possible for humanity with the Next Generation of Anti-Inflammatories.


And remember, for a limited time, and as little as $294, you can impact (and profit from) positively affecting the course of humanity. Invest now HERE. Don't delay, there are 29 days left in this capital campaign. Our traction is palpable, and this is a unique opportunity for everyday investors to own a piece of healthcare history.


Let's do this!

Jim

 

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Sen-Jam Pharmaceutical.

$294.00

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$1,000.00

Tier 1

The Company would like to offer you an additional 3% bonus shares of your total investment.

$5,000.00

Tier 2

The Company would like to offer you an additional 7% bonus shares of your total investment.

$10,000.00

Tier 3

The Company would like to offer you an additional 10% bonus shares of your total investment.

$20,000.00

Tier 4

The Company would like to offer you an additional 12% bonus shares of your total investment.

$25,000.00

Tier 5

The Company would like to offer you an additional 15% bonus shares of your total investment.

$50,000.00

Tier 6

The Company would like to offer you an additional 20% bonus shares of your total investment.

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

PREVIOUSLY CROWDFUNDED
$1,007,201.00
RAISED
$309,476.07
INVESTORS
83
MIN INVEST
$294.00
VALUATION
$69.98M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.